铝碳酸镁咀嚼片是以铝碳酸镁为主要活性成分的口服抗酸药。本品可供咀嚼吞服，可快速缓解酸性胃肠道疾病的症状，例如烧心、胃酸过多、胃酸 反流（ GERD ）、消化性溃疡等。 据 QYResearch 调研团队最新报告"全球铝碳酸镁咀嚼片市场报告 2025-2031 "显示，预计 2031 年全球铝碳酸镁咀嚼片市场规模将达到 3.1 亿美元， 未来几年年复合增长率 CAGR 为 6.5% 。 铝碳酸镁咀嚼片 ，全球市场总体规模 全球 铝碳酸镁咀嚼片 市场前 20 强生产商排名及市场占有率（基于 2 02 4 年调研数据；目前最新数据以本公司最新调研数据为准） 根据 QYResearch 头部企业研究中心调研，全球范围内铝碳酸镁咀嚼片生产商主要包括 Bayer AG 、广东华润顺峰药业、重庆华森制药、江苏万高 药业、湖南九典制药、安丘市鲁安药业、广西南宁百会药业、浙江得恩德制药、海南皇隆制药、特一药业等。 2024 年，全球前十强厂商占有大约 87.0% 的市场份额。 铝碳酸镁咀嚼片 ，全球市场规模，按产品类型细分，原研药处于主导地位 就产品类型而言，目前原研药是最主要的细分产品，占据大约 38.3% 的份额。 铝碳酸 ...

2025 年 08 月 29 日 合作引进，加码创新药研发 买入(首次) 事件 分析师：胡博新 S1050522120002 hubx@cfsc.com.cn | 基本数据 | 2025-08-28 | | --- | --- | | 当前股价（元） | 49.5 | | 总市值（亿元） | 100 | | 总股本（百万股） | 202 | | 流通股本（百万股） | 185 | | 52 周价格范围（元） | 12.26-64.7 | | 日均成交额（百万元） | 234.23 | 市场表现 资料来源：Wind，华鑫证券研究 -100 0 100 200 300 400 500 (%) 昂利康 沪深300 相关研究 —昂利康（002940.SZ）公司事件点评报告 昂利康发布公告：2025 年上半年，公司实现营业总收入 72435.50 万元，同比下降 14.52%；归属于上市公司股东的净 利润 6592.51 万元，同比下降 3.19%。 投资要点 ▌ 把握集采中选品种机遇 公司复方α-酮酸片和合作产品艾地骨化醇软胶囊于 2024 年 中选第十批国家集采，目前已进入进院采购阶段，快速上 量。除参与国采之外， ...

Core Viewpoint - Northeast Pharmaceutical has successfully transformed from traditional manufacturing to innovation-driven development since its mixed-ownership reform in 2018, significantly increasing its R&D investment and establishing itself in the advanced cell therapy sector [1][2]. Group 1: Innovation Strategy and Development - Before the mixed-ownership reform, Northeast Pharmaceutical struggled with slow market responses and insufficient R&D investment. Post-reform, the company has leveraged new advantages to enhance R&D efforts and accurately identify high-potential new drug projects [2]. - The company has adopted a three-pronged approach of "independent R&D + joint development + project introduction," establishing a biological R&D base in Shanghai and acquiring Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., which has a unique technology platform in solid tumor cell therapy [2]. - In the first half of this year, Northeast Pharmaceutical initiated large-scale recruitment of master's and doctoral talents to strengthen its research capabilities, aiming to create a talent hub and technical benchmark in the biopharmaceutical field [2]. Group 2: Technological Achievements - Under the guidance of its innovation strategy, Northeast Pharmaceutical has achieved significant technological results, with 22 new products approved for production in the past four years, including various injection solutions and tablets that have contributed to continuous growth in operating performance [3]. - The company has developed over 10 tumor-targeted cell therapy products for diseases such as pancreatic cancer and colorectal cancer, enhancing its market competitiveness and providing new treatment hopes for patients [3]. - Northeast Pharmaceutical is advancing the construction of intelligent production lines, achieving full-process control and improving production efficiency while ensuring product quality stability and reliability [3]. Group 3: Social Responsibility and Employee Welfare - Northeast Pharmaceutical has invested nearly 300 million yuan in social donations for industrial poverty alleviation, rural revitalization, and pandemic relief, demonstrating its commitment to social responsibility [4]. - The company has established a comprehensive welfare policy system covering healthcare, education, and elderly care, distributing over 1.2 billion yuan in various benefits and cash bonuses to employees since the mixed-ownership reform [4]. - Looking ahead, Northeast Pharmaceutical plans to continue its commitment to social contributions and increase R&D investments in the biopharmaceutical sector to support the "Healthy China" strategy [4].

Core Insights - The health consumption trend is shifting towards fragmented scenarios, leading to increased sales of "small packaging" medications during the "618" shopping festival [1][2] Group 1: Online Trends - The demand for small-dose medications is rising as consumers become more aware of the need to avoid waste and unnecessary stockpiling of medicines [2] - During the "618" event, the order growth rate for small packaging of common household medications significantly outpaced that of larger packages, with specific examples showing a 24% increase for aluminum magnesium carbonate chewable tablets in 20-piece boxes compared to 30-piece boxes [2] - The platform is collaborating with pharmaceutical companies to promote the production of small packaging medications, aiming to guide users towards rational purchasing and reduce waste [2] Group 2: Offline Trends - There is a strong demand for pediatric medications during the summer, with products like children's oseltamivir and Baiyunshan children's banlan root granules becoming popular [3] - A report from a respiratory health conference highlighted the effectiveness of banlan root granules in treating seasonal flu symptoms, showing better safety and efficacy compared to oseltamivir and placebo [3] - Pharmacists emphasize the importance of distinguishing between adult and pediatric medications, advising parents on appropriate treatments for children's common ailments [4]

Core Points - The article emphasizes the importance of gut health for students preparing for the college entrance examination, highlighting the connection between gut issues and academic performance [1][2][3] Group 1: Gut Health and Its Impact - The gut is referred to as the "second brain," containing approximately 100 million nerve cells that communicate with the brain through the gut-brain axis [2] - Gut problems during the exam period can manifest as a triad of symptoms: acute onset abdominal pain, chronic bloating, and anxiety, which can negatively affect exam performance [2][3][4] Group 2: Dietary Recommendations - Students are advised to avoid three dietary pitfalls: high-fat foods, cold and raw foods, and excessive intake of coarse grains [5] - A suggested nutritional pyramid includes prioritizing low glycemic index carbohydrates, adequate protein intake, and essential micronutrients to support gut health [5][6] Group 3: Emergency Preparedness - Recommendations for an emergency kit include medications for diarrhea, stomach pain relief, and oral rehydration solutions [11][18] - Students should be aware of how to manage sudden gastrointestinal symptoms during exams, including specific remedies for diarrhea and constipation [16][17] Group 4: Stress Management Techniques - The article outlines self-help methods for anxiety reduction, such as breathing exercises and visualization techniques [13][15] - Physical activity is encouraged, with a focus on light exercise to promote gut motility without causing fatigue [10][15] Group 5: General Health Tips - Students are advised to maintain a consistent sleep schedule, avoid new foods before exams, and ensure proper hydration [8][9][20] - Parents are encouraged to support their children by creating a healthy environment and reducing unnecessary pressure [20][21]

Financial Performance - In 2024, the company achieved operating revenue of 774 million yuan, a year-on-year increase of 12.04% [1] - The net profit attributable to shareholders reached 76.73 million yuan, a significant year-on-year growth of 134.66% [1] - The net profit after deducting non-recurring gains and losses was 51.21 million yuan, up 146.94% year-on-year [1] - Basic earnings per share were 0.18 yuan [1] Profitability Metrics - The gross profit margin for 2024 was 57.27%, an increase of 2.30 percentage points year-on-year [3] - The net profit margin improved to 9.90%, up 5.17 percentage points year-on-year [3] - The weighted average return on net assets was 4.68%, an increase of 2.65 percentage points year-on-year [3] Expense and Cash Flow Analysis - Total period expenses for 2024 amounted to 357 million yuan, a year-on-year increase of 7.03% [3] - Selling expenses were 251 million yuan, up 18.88% year-on-year due to increased academic promotion activities [3] - Research and development expenses decreased by 24.31% to 59.13 million yuan [3] - Net cash flow from operating activities was 162 million yuan, down 26.25% year-on-year [3] - Net cash outflow from investing activities was 107 million yuan, primarily for production base construction and smart transformation [3] Business Segment Performance - Revenue from the pharmaceutical industry was 651 million yuan, a year-on-year increase of 15.39%, accounting for 84.02% of total revenue [3] - Revenue from ear, nose, and throat medications was 265 million yuan, up 28.26% year-on-year [3] - Revenue from digestive system medications reached 178 million yuan, a year-on-year increase of 11.46% [3] - Revenue from psychiatric and neurological medications was 145 million yuan, up 14.06% year-on-year [3] New Business Developments - The company received approval for the special medical food project TY005, with production lines gradually releasing capacity [4] - E-commerce sales exceeded 13 million yuan [4] - The company is advancing four tumor-related Class 1 new drug pipelines, with the HSN003 project entering the IND application preparation stage [4] - A cash dividend of 0.50 yuan per 10 shares (including tax) is proposed for 2024 [4]